SYRS Stock - Syros Pharmaceuticals, Inc.
Unlock GoAI Insights for SYRS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $9.94M | $14.88M | $23.49M | $15.09M | $1.98M |
| Gross Profit | $7.68M | $11.91M | $23.49M | $15.09M | $1.98M |
| Gross Margin | 77.3% | 80.1% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-128,988,000 | $-135,873,000 | $-99,420,000 | $-82,297,000 | $-77,741,000 |
| Net Income | $-164,574,000 | $-94,654,000 | $-86,558,000 | $-84,038,000 | $-75,438,000 |
| Net Margin | -1656.3% | -636.1% | -368.5% | -556.8% | -3806.2% |
| EPS | $-5.81 | $-7.49 | $-13.84 | $-18.25 | $-18.76 |
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteEarnings History & Surprises
SYRSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 29, 2025 | — | — | — | — |
Q3 2025 | Aug 4, 2025 | — | — | — | — |
Q2 2025 | May 20, 2025 | $-0.70 | — | — | — |
Q1 2025 | Mar 26, 2025 | $-0.70 | $-1.19 | -70.0% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $-0.76 | $-0.68 | +10.5% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $-0.79 | $-0.70 | +11.4% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.89 | $-0.79 | +11.2% | ✓ BEAT |
Q1 2024 | Mar 27, 2024 | $-1.23 | $-1.19 | +3.3% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-1.12 | $-1.35 | -20.5% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-1.11 | $-1.30 | -17.1% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-1.12 | $-0.85 | +24.1% | ✓ BEAT |
Q1 2023 | Mar 2, 2023 | $-1.27 | $-1.28 | -0.8% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-3.91 | $-2.41 | +38.4% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-4.20 | $-5.40 | -28.6% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-4.80 | $-4.00 | +16.7% | ✓ BEAT |
Q1 2022 | Mar 15, 2022 | $-4.40 | $-4.20 | +4.5% | ✓ BEAT |
Q4 2021 | Nov 5, 2021 | $-4.30 | $-4.10 | +4.7% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-3.60 | $-3.60 | 0.0% | = MET |
Q2 2021 | May 6, 2021 | $-5.50 | $-2.30 | +58.2% | ✓ BEAT |
Q1 2021 | Mar 4, 2021 | $-5.40 | $-6.10 | -13.0% | ✗ MISS |
Latest News
Frequently Asked Questions about SYRS
What is SYRS's current stock price?
What is the analyst price target for SYRS?
What sector is Syros Pharmaceuticals, Inc. in?
What is SYRS's market cap?
Does SYRS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SYRS for comparison